Loading…
Loading…
BIIB does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for BIIB and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for BIIB and 80,000+ other tickers.
See exactly how BIIB's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for BIIB and 80,000+ other tickers.
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a…
Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
[url="]Stoke Therapeutics, Inc.[/url] (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential wit
Biogen is rated Hold ahead of Q3 2026 earnings, with cautious optimism due to pipeline catalysts and improving growth portfolio performance. MS franchise and Alzheimer's therapies face patent expiries, competition, and limited efficacy, pressuring BIIB to deliver new blockbuster products. Growth hinges on pipeline readouts, especially litifilimab in SLE, while subQ Leqembi, Spinraza high dose, Syfovre, and Empaveli are key near-term revenue drivers.
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
On October 20, 2026, Biogen Inc (BIIB) shares rose 4.1% to a current price of $243.10. This increase comes in the context of a 52-week range that saw lows of $1